Up next

Autoplay

PM1183 plus doxorubicin shows interesting activity in small cell lung cancer

2 Views • 07/14/23
Share
Embed
administrator
administrator
Subscribers
0

Visit http://www.ecancer.org for more

Dr Calvo (START Madrid, Madrid, Spain) talks to ecancertv at ASCO 2015 about data from a Phase 1b study of the transcriptional inhibitor PM1183 in combination with doxorubicin in second line therapy in patients with small cell lung cancer (SCLC)

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay